A novel mitragynine analog with low efficacy mu-opioid receptor agonism displays antinociception with attenuated adverse effects
Authors:
- Soumen ChakrabortySCSoumen Chakraborty
- Jeffrey F. DiBertoJDJeffrey F. DiBerto
- Abdelfattah FaouziAFAbdelfattah Faouzi
- Sarah M. BernhardSBSarah M. Bernhard
- Anna M. GutridgeAGAnna M. Gutridge
- Steven RamseySRSteven Ramsey
- Davide ProvasiDPDavide Provasi
- Nitin NuthikattuNNNitin Nuthikattu
- Rahul JilakaraRJRahul Jilakara
- Melissa N.F. NelsonMNMelissa N.F. Nelson
- Wesley B. AsherWAWesley B. Asher
Preprint
Abstract
Dried kratom leaves are anecdotally used for the treatment of pain, opioid dependence, and alcohol use disorder. We have previously shown that kratom’s natural products (mitragynine) and semi-synthetic analogs (7-hydroxy mitragynine (7OH) and mitragynine pseudoindoxyl) are mu opioid receptor (MOR) agonists that show minimal β-arrestin2 recruitment. To further investigate the structure activity relationships of G-protein potency, efficacy, and β-arrestin2 recruitment, we diversified the mitragynine/7OH templates at the C9, -10 and -12 positions of the aromatic ring of the indole moiety. Three lead C9 analogs, synthesized by swapping the 9-methoxy group with varied substituents, namely phenyl ( SC11 ), methyl ( SC12 ), 3’-furanyl ( SC13 ), were further characterized using a panel of in vitro and ex vivo electrophysiology assays. All three compounds were partial agonists with lower efficacy than both DAMGO and morphine in heterologous G-protein assays and synaptic physiology. SC11-13 also showed lower recruitment of both β-arrestin subtypes compared to DAMGO, and in assays with limited MOR receptor reserve, the G-protein efficacy of SC11, SC12 and SC13 was comparable to buprenorphine. In mouse models, at equianalgesic doses SC13 showed MOR-dependent analgesia with potency similar to morphine without respiratory depression, hyperlocomotion, constipation, or place conditioning. Taken together, these results suggest that MOR agonists with a G-protein efficacy profile similar to buprenorphine can be developed into opioids that are effective analgesics with greatly reduced liabilities.Keywords
All Related Versions
- Published version: Journal of Medicinal Chemistry, 64 (18), 13873.
This publication has 60 references indexed in Scilit:
- Efficacy and ligand bias at the μ‐opioid receptorBritish Journal of Pharmacology, 2013
- Buprenorphine Metabolites, Buprenorphine-3-glucuronide and Norbuprenorphine-3-glucuronide, Are Biologically ActiveAnesthesiology, 2011
- μ-Opioid Receptors: Correlation of Agonist Efficacy for Signalling with Ability to Activate InternalizationMolecular Pharmacology, 2010
- Constructing the equilibrium ensemble of folding pathways from short off-equilibrium simulationsProceedings of the National Academy of Sciences of the United States of America, 2009
- Clustering by Passing Messages Between Data PointsScience, 2007
- 75 years of opioid research: the exciting but vain quest for the Holy GrailBritish Journal of Pharmacology, 2006
- Morphine Side Effects in β-Arrestin 2 Knockout MiceThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Synergistic Contributions of the Functional Groups of Epinephrine to Its Affinity and Efficacy at the β2 Adrenergic ReceptorMolecular Pharmacology, 2004
- Antinociceptive effect of 7-hydroxymitragynine in mice: Discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosaLife Sciences, 2004
- Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomesLife Sciences, 1997